Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma

Table 1

Size of target lesions (measurements of the largest diameter).

	Baseline	Follow-up
	Target lesions
T1 paravertebral	2.34 cm (Figure 2(c))	1.76 cm (Figure 2(d))
T2 abdominal wall	1.98 cm (Figure 2(e))	1.56 cm (Figure 2(f))
Sum	4.32 cm	3.32 cm (−23.1%)
	Nontarget lesions
T3 paravertebral	1.80 cm (Figure 2(a))	1.18 cm (Figure 2(b))
T4 paravertebral	1.71 cm (Figure 2(c))	1.42 cm (Figure 2(d))
T5 abdominal wall	1.34 cm (Figure 2(g))	1.32 cm (Figure 2(h))